In metastatic prostate cancer and advanced melanoma patients, ipilimumab treatment induced a significant increase in Ag-specific humoral and CTL responses, while levels of suppressive FoxP3+ Tregs remained stable or were expanded [66,139,141]. The gene discussed is FOXP3; the disease is melanoma.